Who We Are

We are a small molecule, anti-infective company.

Microbiotix, Inc. is a privately held, product-focused biopharmaceutical company engaged in the discovery and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company currently has four novel compound series in research and development.

Microbiotix has an active research program to discover a broad-spectrum antibiotic that targets DNA replication of drug-resistant Gram-positive and Gram-negative bacteria. In addition to a Gram-positive antibiotic (MBX500), our most advanced antiviral compounds target cytomegalovirus (CMV) ( MBX400) and are in preclinical development.

Microbiotix also has an active biodefense program, focused on novel therapeutics for Bacillus anthracis and Burkholderia pseudomallei and is also actively involved in the discovery of inhibitors of bacterial biofilm formation and antibiotic resistance.

What's New

Click on the book or date to the left of any item below for more information.

08/15/2011 - Microbiotix received a NIH/NIAID STTR Phase I grant to develop an innovative catheter coating effective in preventing select catheter colonization.

08/01/2011 - Microbiotix received a NIH/NIAID SBIR Phase II grant to optimize the phenoxyacetamide series of T3SS inhibitors and establish potency and selectivity in animal models of P. aeruginosa infection.

04/01/2011 - Microbiotix received a NIH/NIAID SBIR Phase I grant to develop a novel class of botulinum neurotoxin A inhibitors into novel therapeutics.

07/01/2010 - Microbiotix received a NIAID R01 grant to discover and develop small molecule theraputic aganes agains Ebola virus to respond to natural outbreaks of Ebola virus infection and to counter potential acts of bioterrorism.

03/01/2010 - Microbiotix received a NIAID SBIR Phase I grant to discover, develop, and synthesize small molecule inhibitors of Sortase A for anti-infective therapy, e.g. for the treatment of Gram-positive bacterial infection.